Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Merck KGaA. (3/2/20). "Press Release: Erbitux Approved for First-Line Use in China in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) [Not intended for UK-based media]". Darmstadt.

Region Region China
Organisations Organisation Merck KGaA
  Group Merck (DE) (Group)
  Organisation 2 National Medical Products Administration of China (NMPA, formerly CFDA)
  Group China (govt)
Products Product Erbitux®
  Product 2 fluorouracil (INN)
     


   
Record changed: 2020-03-11

Advertisement

Picture [iito] – Putting Information into Context 650x65px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top